Therapeutic effect of sodium alginate in experimental chronic ulcerative colitis

Iranian Journal of Allergy, Asthma and Immunology

Volumn 7, Issue 1, 2008, Pages 13-18

  Razavi, Alireza ^a   Khodadadi, Ali ^b   Eslami, Mohammad Bagher ^a   Eshraghi, Saeed ^a   Mirshafiey, Abbass ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Colitis; Inflammatory bowel disease treatment; Sodium alginate

Indexed keywords

ALGINIC ACID; CYTOKINE; ICOSANOID; INTERLEUKIN 6; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; ENTERITIS; FEMALE; NONHUMAN; RAT; ULCERATIVE COLITIS;

ALGINATES; ANIMALS; CHRONIC DISEASE; COLITIS, ULCERATIVE; DINOPROSTONE; FEMALE; GLUCURONIC ACID; HEMOSTATICS; HEXURONIC ACIDS; IMMUNITY, MUCOSAL; INTERLEUKIN-6; LEUKOTRIENE B4; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR-ALPHA;

EID: 42149123798     PISSN: 17351502     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Zhang Z, Hinrichs DJ, Lu H, Chen H, Zhong W, Kolls JK. After interleukin-12p40, are interleukin-23 and interleukin-17 the next therapeutic targets for inflammatory bowel disease? Int Immunopharmacol 2007; 7(4):409-16.
2. Sands BE. Inflammatory bowel disease: past, present, and future. J Gastroenterol 2007; 42(1):16-25.
3. Kreisel W. Pathogenesis of chronic inflammatory bowel diseases. Schweiz Rundsch Med Prax 2006; 95(50):1965-73.
4. Dobosz M, Mionskowska L, Dobrowolski S, Dymecki D, Makarewicz W, Hrabowska M, et al. Is nitric oxide and heparin treatment justified in inflammatory bowel disease? An experimental study. Scand J Clin Lab Invest 1996; 56(7):657-63.
5. Hanauer S. Medical therapy of ulcerative colitis. Lancet 1993; 342(8868):412-7.
6. Skjak-Braek G, Grasdalen H, Larson B. Monomer sequence and acetylation pattern in some bacterial alginates. Carbohydr Res 1986; 15:239-50.
7. Bucke C. Cell immobilization in calcium alginate. Methods Enzymol 1987; 135:175-88.
8. Rehm BH. Alginate lyase from pseudomonas aeruginosa CF1/M1 prefers the hexameric oligomannuronate as substrate. FEMS Microbiol Lett 1998; 165(1):175-80.
9. Rehm BH, Valla S. Bacterial alginates: biosynthesis and applications. Appl Microbiol Biotechnol 1997; 48(3):281-8.
10. Odell EW, Oades P, Lombardi T. Symptomatic foreign body reaction to haemostatic alginate. Br J Oral Maxillofac Surg 1994; 32(3):178-9.
11. Lanza RP, Kuhtreiber WM, Ecker DM, Marsh JP, Chick WL. Transplantation of porcine and bovine islets into mice without immunosuppression using uncoated alginate microspheres. Transplantation proceedings 1995; 27(6):3321-1.
12. Lee JH, Kim WG, Kim SS, Lee JH, Lee HB. Development and characterization of an alginate-impregnated polyester vascular graft. J Biomed Mater Res 1997; 36(2):200-8.
13. Kuipers ME, Heegsma J, Bakker HI, Meijer DK, Swart PJ, Frijlink EW, et al. Design and fungicidal activity of mucoadhesive lactoferrin tablets for the treatment of oropharyngeal candidosis. Drug Deliv 2002; 9(1):31-8.
14. Streitenberger SA, Villaverde MJ, Sanchez-Ferrer A, Garcia-Carmona F. Microencapsulation of aerococus liridans with catalase and its application for the synthesis of dihydroxyacetone phosphate. Appl Microbiol Biotechnol 2002; 58(1):73-6.
15. Efentakis M, Buckton G. The effect of erosion and swelling on the dissolution of theophylline from low and high viscosity sodium alginate matrices. Pharm Dev Technol 2002; 7(1):69-77.
16. Asada M, Sugie M, Inoue M, Nakagomi K, Hongo S, Murata K, et al. Inhibitory effect of alginic acids on hyaluronidase and on histamine release from mast cells. Biosci Biotech Biochem 1997; 61(6):1030-2.
17. Hasegawa T, Takahashi T, Inada Y, Yamada C, Tanaka Y. Reparative effects of sodium alginate (Alloid G) on radiation stomatitis. Nippon Igaku Hoshasen Gakkai Zasshi 1989; 49(8):1047-51.
18. Oshitani T, Okada K, Kushima T, Suematsu T, Obayashi k, Hirata Y, et al. Clinical evaluation of sodium alginate on oral mucositis associated with radiotherapy. Nippon Gan chiryo Gakkai shi 1990; 25(6):1129-34.
19. Gong YF, Huang ZJ, Qiang MY, an FX, Bai GA, Mao YX, et al. Suppression of radioactive strontium absorption by sodium alginate in animals and human subjects. Biomed Environ Sci 1991; 4(3):237-82.
20. Mirshafiey A, Khodadadi A, Rehm BH, Khorramizadeh MR, Eslami MB, Razavi A, et al. Sodium alginate as a novel therapeutic option in experimental colitis. Scand J Immunol 2005; 61(4):316-21.
21. Mirshafiey A, Borzooy Z, Abhari RS, Razavi A, Tavangar M, Rehm BH. Treatment of experimental immune complex glomerulonephritis by sodium alginate. Vascul Pharmacol 2005; 43(1):30-5.
22. Menozzi A, Pozzoli C, Poli E, Lazzaretti M, Grandi D, Coruzzi G. Long-term study of TNBS-induced colitis in rats: focus on mast cells. Inflamm Res 2006; 55(10):416-22.
23. Talero E, Sanchez-Fidalgo S, Calvo JR, Motilva V. Chronic administration of galanin attenuates the TNBS-induced colitis in rats. Regul Pept 2007; 141(1-3):96-104.
24. Qiao LY, Grider JR. Up-regulation of calcitonin gene-related peptide and receptor tyrosine kinase TrkB in rat bladder afferent neurons following TNBS colitis. Exp Neurol 2007; 204(2):667-79.
25. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 1989; 96(3):795-803.
26. Wallace JL, MacNaughton WK, Morris GP, Beck PL. Inhibition of leukotriene synthesis markedly accelerates healing in a rat model of inflammatory bowel disease. Gastroenterology 1989; 96(1):29-36.
27. Abreu MT, Sparrow MP. Translational research in inflammatory bowel disease. Mt Sinai J Med 2006; 73(8):1067-73.
28. Pizarro TT, Cominelli F. Cytokine therapy for Crohn's disease: advances in translational research. Annu Rev Med 2007; 58:433-44.
29. Gasche C, Reinisch W, Lochs H, Gangl A. Interleukin-6 production in Crohn's disease. Gastroenterol 1992; 103:1120-1.
30. Gross V, Andus T, Caesar I, Roth M, Scholmerich J. Evidence for continuous stimulation of interleukin 6 production in Crohn's disease. Gastroenterol 1992; 102(2):514-9.
31. Braegger CP, Nicholis S, Murch SH, Stephens S, MacDonald TT. Tumour necrosis factor alpha in stool as a marker of intestinal inflammation. Lancet 1992; 329:89-91.
32. Zhou YH, Yu JP, Liu YF, Teng XJ, Ming M, Lv P, et al. Effects of Ginkgo biloba extract on inflammatory mediators (SOD, MDA, TNF-alpha, NF-kappaBp65, IL-6) in TNBS-induced colitis in rats. Mediators Inflamm 2006; 2006(5):92642.
33. Sharon P, Stenson WF. Enhanced synthesis of leukotriene B4 by colonic mucosa in inflammatory bowel disease. Gastroenterology 1984; 86(3):453-60.
34. QIU BS, Pfeiffer CJ, Keith JC jr. Protection by recombinant human interleukin-11 against experimental TNB-induced colitis in rats. Dig Dis Sci 1996; 41(8):1625-30.
35. Raithel M, Matek M, Baenkler HW, Jorde W, Hahn EG. Mucosal histamine content and histamine secretion in Crohn's disease, ulcerative colitis and allergic enteropathy. Int Arch Allergy Immunol 1995; 108(2):127-33
36. Fox CC, Lazenby AJ, Moore WC, Yardley JH, Bayless TM, Lichtenstein LM. Enhancement of human intestinal mast cell mediator release in active ulcerative colitis. Gastroenterology 1990; 99(1):119-24.
37. Winterkamp S, Weidenhiller M, Otte P, Stolper J, Schwab D, Hahn EG, et al. Urinary excretion of N-methylhistamine as a marker of disease activity in inflammatory bowel disease. Am J Gastroenterol 2002; 97(12):3071-7.
38. Heller W, Durst J, Stockeler R. Value of beta glucuronidase and hyaluronidase determination in Crohn's disease and ulcerative colitis. Med Welt 1979; 30(40):1472-7.
39. Van der Wiel-Korslanje JA, Winkler KC. The faecal flora in ulcerative colitis. J Med Microbiol 1975; 8(4):491-501.
40. Agren MS. Four alginate dressings in the treatment of partial thickness wounds: a comparative experimental study. B J Plast surg 1996; 49(2):129-134.